Advertisement

Topics

GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Company Profile

14:06 EDT 21st September 2018 | BioPortfolio

IAVI is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates. In addition, IAVI conducts policy analyses and serves as an advocate for the AIDS vaccine field. IAVI supports a comprehensive approach to addressing HIV and AIDS that balances the expansion and strengthening of existing HIV-prevention and treatment programs with targeted investments in the design and development of new tools to prevent HIV. IAVI is dedicated to ensuring that a future AIDS vaccine will be available and accessible to all who need it. IAVI’s Innovation Fund supports the application of novel and unconventional technologies to AIDS vaccine design and development, and is partially supported by the Bill & Melinda Gates Foundation. IAVI relies on the generous donations from governments, private individuals, corporations and foundations to carry out its mission. For more information, see www.iavi.org.


News Articles [2583 Associated News Articles listed on BioPortfolio]

[Comment] A new step towards an HIV/AIDS vaccine

A preventive vaccine is an essential part of the strategy to eradicate the HIV pandemic.1 Although the search for an AIDS vaccine has led to many scientific advances, a vaccine remains out of reach. M...

AIDS vaccine offers hope in early trial – The Hindu

The HinduAIDS vaccine offers hope in early trialThe HinduThe near 40-year quest for an AIDS vaccine received a hopeful boost on Saturday when scientists announced that a trial drug triggered an immune...

Seqirus to join universal flu vaccine initiative

Manufacturer of egg-based influenza vaccines in the UK, Seqirus, has revealed it is joining the Human Vaccines Project’s Universal Influenza Vaccine Initiative (UIVI) — a collaborative effort to a...

Global HIV/AIDS Diagnostics Market 2017-2022 – HIV/HIV-1/2/Combo, HIVAg/ NAT, Western Blot, HTLV-I/II – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global HIV/AIDS Diagnostics Market 2017-2022” report has been added to ResearchAndMarkets.com’s offering. Global HIV/AIDS Diagnostics Market 2...

World marks HIV Vaccine Awareness Day – New Vision

New VisionWorld marks HIV Vaccine Awareness DayNew VisionVACCINE FOR HIV. HEALTH- Twenty-one years ago today, Bill Clinton, American president then, said: “It is no longer a question of whether we c...

Share offering brings in $119M for GlycoMimetics

The sale of 7 million shares priced at $17 raised $119 million for GlycoMimetics.  -More- 

[Comment] The Lancet Commission on malaria eradication

20 years ago, infectious diseases dominated the global health agenda. Policy makers, researchers, implementers, and donors united in the fight against infectious diseases, creating the Millennium Deve...

2018 OrthoClinical Diagnostics: Market Shares and Competitive Position by Product and CountryPerformance, Capabilities, Goals and Strategies in the Global Diagnostics Industry [Report Updated: 01011970] Prices from USD $3850

This unique market intelligence report from VPGMarketResearch provides information not available from any other published source. The report includes diagnostics sales and market share estimates by pr...

PubMed Articles [2462 Associated PubMed Articles listed on BioPortfolio]

Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India.

A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was conducted in India in 2009 to test a subtype C prophylactic vaccine in a prime-boost regimen comprising ...

Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland Tanzania.

Monovalent rotavirus vaccine (RV1) was introduced in Tanzania in January 2013 under the Reach Every Child initiative, to be given at ages 6 and 10 weeks. We used the sentinel hospital rotavirus surv...

Monkey Models and HIV Vaccine Research.

Since the discovery of acquired immunodeficiency syndrome (AIDS) in 1981, it has been extremely difficult to develop an effective vaccine or a therapeutic cure despite over 36 years of global efforts...

Prospects for a vaccine to prevent HIV-related tuberculosis.

To outline the need for a new tuberculosis (TB) vaccine; challenges for induction of vaccine-mediated protection in HIV-infected persons; and recent advances in clinical development.

Introduction to the Special Issue: Ending the AIDS Pandemic by 2030: Accelerating Efforts to Prevent HIV.

Clinical Trials [5684 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndr...

Development of a New HIV Vaccine

The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore...

Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)

Major Research Aim: To study novel molecular diagnostics and the pharmacokinetic variability among a spectrum of TB disease states, including severe forms of TB like disseminated TB, TB me...

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines ...

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk o...

Companies [2959 Associated Companies listed on BioPortfolio]

GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC

IAVI is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Found...

IAVI

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV ...

International AIDS Vaccine Initiative

The International AIDS Vaccine Initiative (IAVI)

The International AIDS Vaccine Initiative

More Information about "GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC" on BioPortfolio

We have published hundreds of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC news stories on BioPortfolio along with dozens of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Clinical Trials and PubMed Articles about GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Companies in our database. You can also find out about relevant GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record